Cargando…

Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”

Correction to: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases 2020; 8: 1361-1384. We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital, China Medical University. Now we...

Descripción completa

Detalles Bibliográficos
Autor principal:	Sang, Li-Xuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281406/ https://www.ncbi.nlm.nih.gov/pubmed/34307635 http://dx.doi.org/10.12998/wjcc.v9.i20.5752

Ejemplares similares

Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases
por: Cheng, Fang-Shu, et al.
Publicado: (2020)

Correction: The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2022)

Correction: Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

Correction: Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
Publicado: (2014)

The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2013)

Probiotic Therapy With VSL#3(®) in Patients With NAFLD: A Randomized Clinical Trial
por: Derosa, Giuseppe, et al.
Publicado: (2022)

Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(−/−) mice
por: Chan, Yee Kwan, et al.
Publicado: (2016)

Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

The Probiotic Mixture VSL#3 Dampens LPS-Induced Chemokine Expression in Human Dendritic Cells by Inhibition of STAT-1 Phosphorylation
por: Mariman, Rob, et al.
Publicado: (2014)

Probiotic mixture VSL#3 prevents ulcerative colitis-associated carcinogenesis in mice and cells by regulating the inflammatory and Wnt/β-catenin pathway
por: Li, Wenbin, et al.
Publicado: (2022)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner
por: Isidro, Raymond A., et al.
Publicado: (2014)

Probiotic colonization dynamics after oral consumption of VSL#3(®) by antibiotic-treated mice
por: Theriot, Casey, et al.
Publicado: (2022)

Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
por: Rashid, Sherzad K., et al.
Publicado: (2014)

Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

PReS-FINAL-2074: The role of the probiotic VSL-3 as adjuvant therapy in patients with undifferentiated spondyloarthritis (ERA)
por: Vidovic, M, et al.
Publicado: (2013)

Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome
por: Distrutti, Eleonora, et al.
Publicado: (2013)

VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer
por: Arthur, Janelle C., et al.
Publicado: (2013)

Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation
por: Kim, Seong-Eun, et al.
Publicado: (2015)

Development of omics‐based protocols for the microbiological characterization of multi‐strain formulations marketed as probiotics: the case of VSL#3
por: Mora, Diego, et al.
Publicado: (2019)

Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome
por: Boonma, Prapaporn, et al.
Publicado: (2021)

Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP
por: Distrutti, Eleonora, et al.
Publicado: (2014)

Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial
por: Sinha, Anju, et al.
Publicado: (2015)

The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
por: Vicari, Enzo, et al.
Publicado: (2017)

A randomised placebo controlled trial of VSL#3(®) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease
por: Chong, Pui Lin, et al.
Publicado: (2021)

Heat-killed VSL#3 Ameliorates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis in Rats
por: Sang, Li-Xuan, et al.
Publicado: (2013)

VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice
por: Wang, Chun-Sai-Er, et al.
Publicado: (2018)

The Probiotic VSL#3(®) Does Not Seem to Be Efficacious for the Treatment of Gastrointestinal Symptomatology of Patients with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Calandre, Elena P., et al.
Publicado: (2021)

Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment
por: Dolpady, Jayashree, et al.
Publicado: (2016)

Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis
por: Dang, Xiaofei, et al.
Publicado: (2020)

Effect of a probiotic preparation (VSL#3) in critically ill patients: A randomized, double-blind, placebo-controlled trial (Pilot Study)
por: Ebrahimi-Mameghani, Mehrangiz, et al.
Publicado: (2013)

Mechanism of Probiotic VSL#3 Inhibiting NF-κB and TNF-α on Colitis through TLR4-NF-κB Signal Pathway
por: WANG, Hui, et al.
Publicado: (2019)

The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury
por: Chang, Bing, et al.
Publicado: (2013)

Effect of Probiotic (VSL#3) and Omega-3 on Lipid Profile, Insulin Sensitivity, Inflammatory Markers, and Gut Colonization in Overweight Adults: A Randomized, Controlled Trial
por: Rajkumar, Hemalatha, et al.
Publicado: (2014)

Comparison of Microbiological, Histological, and Immunomodulatory Parameters in Response to Treatment with Either Combination Therapy with Prednisone and Metronidazole or Probiotic VSL#3 Strains in Dogs with Idiopathic Inflammatory Bowel Disease
por: Rossi, Giacomo, et al.
Publicado: (2014)

The Epithelial Barrier Model Shows That the Properties of VSL#3 Depend from Where it is Manufactured
por: Palumbo, Paola, et al.
Publicado: (2019)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

Probiotic Formulation VSL#3 Interacts with Mesenchymal Stromal Cells To Protect Dopaminergic Neurons via Centrally and Peripherally Suppressing NOD-Like Receptor Protein 3 Inflammasome-Mediated Inflammation in Parkinson’s Disease Mice
por: Zhou, Liping, et al.
Publicado: (2023)

VSL#3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial
por: Rohatgi, Sarika, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rgqrj0qc25696rhg048i80cdn5